Transplant
Mouse studies suggest agonizing RIG-I or STING could help prevent allogeneic bone marrow transplant (BMT)-induced GvHD. In a mouse model of the disease, pretreatment of recipients with a triphosphate RNA-based RIG-I agonist increased survival and decreased weight loss, small intestine permeability, systemic bacteremia and allogeneic T cell activation in the spleen and intestine compared with no pretreatment. Also in the model, pretreatment with a DNA-based STING agonist increased survival and decreased weight loss and small intestine permeability. Next steps include clinical testing of the RIG-I or STING agonist in patients undergoing allogeneic BMT.
Rigontec GmbH has the synthetic RIG-I agonist ImOI100 (RGT100) in Phase I/II testing for lymphoma and solid tumors...